CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable. Media contact: pr@carsgen.com
View Top Employees from CARsgen TherapeuticsWebsite | http://www.carsgen.com |
Revenue | $55.7 million |
Funding | $216 million |
Employees | 150 (150 on RocketReach) |
Founded | 2014 |
Phone | +86 21 5448 9928 |
Technologies |
JavaScript,
HTML,
Google Analytics
+6 more
(view full list)
|
Industry | Biotechnology, Business Services General, Immunotherapy, Business Services, Solid Tumor, CAR-T |
Web Rank | 6 Million |
Keywords | Hematologic Malignancies, Solid Tumors, Biopharmaceuticals, Innovative Therapies, Clinical Trials |
Competitors | Arcus Biosciences, Legend Biotech, Lyell Immunopharma, Sorrento Therapeutics, Inc., Y-mAbs Therapeutics, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular CARsgen Therapeutics employee's phone or email?
The CARsgen Therapeutics annual revenue was $55.7 million in 2024.
Leigh Hsu is the Senior Vice President, Business Development of CARsgen Therapeutics.
150 people are employed at CARsgen Therapeutics.
The NAICS codes for CARsgen Therapeutics are [3254, 325, 32, 32541].
The SIC codes for CARsgen Therapeutics are [28, 283].